According to the checkpoint blockade hypothesis [1], anti-CTLA-4 antibodies cause tumor rejection by promoting priming of naïve T cells through blocking the inhibitory B7-CTLA-4 signaling in peripheral lymphoid organs (Fig. 1). The gene discussed is CTLA4; the disease is neoplasm.